Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 13;11(5):74.
doi: 10.3390/bs11050074.

Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors

Paulina Gonzalez-Latapi  1 , Ece Bayram  2 , Irene Litvan  2 , Connie Marras  1
Affiliations
Review

Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors

Paulina Gonzalez-Latapi et al. Behav Sci (Basel). .

Abstract

Cognitive impairment is a common non-motor symptom in Parkinson's Disease (PD) and an important source of patient disability and caregiver burden. The timing, profile and rate of cognitive decline varies widely among individuals with PD and can range from normal cognition to mild cognitive impairment (PD-MCI) and dementia (PDD). Beta-amyloid and tau brain accumulation, oxidative stress and neuroinflammation are reported risk factors for cognitive impairment. Traumatic brain injury and pesticide and tobacco exposure have also been described. Genetic risk factors including genes such as COMT, APOE, MAPT and BDNF may also play a role. Less is known about protective factors, although the Mediterranean diet and exercise may fall in this category. Nonetheless, there is conflicting evidence for most of the factors that have been studied. The use of inconsistent criteria and lack of comprehensive assessment in many studies are important methodological issues. Timing of exposure also plays a crucial role, although identification of the correct time window has been historically difficult in PD. Our understanding of the mechanism behind these factors, as well as the interactions between gene and environment as determinants of disease phenotype and the identification of modifiable risk factors will be paramount, as this will allow for potential interventions even in established PD.

Keywords: Parkinson’s disease; clinical profile; dementia; mild cognitive impairment; risk factors.

PubMed Disclaimer

Conflict of interest statement

P.G.L and E.B. declare no conflict of interest. I.L. research is supported by the National Institutes of Health grants: 2R01AG038791-06A, U01NS090259, U01NS100610, U01NS80818, R25NS098999, P20GM109025; U19 AG063911-1 and 1R21NS114764-01A1; the Michael J Fox Foundation, Parkinson Foundation, Lewy Body Association, Roche, Abbvie, Biogen, Centogene. EIP-Pharma, and Biohaven Pharmaceuticals. She was a member of the Scientific Advisory Board of Lundbeck and is a Scientific advisor for Amydis. She receives her salary from the University of California San Diego and as Chief Editor of Frontiers in Neurology. C.M. receives research support from the Michael J Fox Foundation, the Canadian Institutes of Health Research, the Parkinson’s Foundation (US) and the International Parkinson and Movement Disorder Society, is a site investigator for a research study supported by Theravance Biopharma.

Figures

Figure 1
Figure 1
Protective and risk factors for cognitive impairment. Factors associated with cognitive impairment are classified as either protective or risk factors. Established factors in each category are shown in solid colors. Factors where the association remains uncertain are shown in light colors and emphasized with a question mark. Possible interactions and mechanisms of action are displayed by connecting arrows and brackets. APOE = Apolipoprotein E; BDNF = Brain-derived neurotrophic factor; BMI = body mass index; COMT = Catechol-O-methyltransferase; DM = diabetes mellitus; HTN = hypertension; MAPT = Microtubule-associated protein tau; REM = rapid eye movement; UA = uric acid. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Levy G., Tang M.X., Louis E.D., Cote L.J., Alfaro B., Mejia H., Stern Y., Marder K. The association of incident dementia with mortality in PD. Neurology. 2002;59:1708–1713. doi: 10.1212/01.WNL.0000036610.36834.E0. - DOI - PubMed
    1. Winter Y., von Campenhausen S., Arend M., Longo K., Boetzel K., Eggert K., Oertel W.H., Dodel R., Barone P. Health-related quality of life and its determinants in Parkinson’s disease: Results of an Italian cohort study. Parkinsonism Relat. Disord. 2011;17:265–269. doi: 10.1016/j.parkreldis.2011.01.003. - DOI - PubMed
    1. Lang A.E., Obeso J.A. Time to move beyond nigrostriatal dopamine deficiency in Parkinson’s disease. Ann. Neurol. 2004;55:761–765. doi: 10.1002/ana.20102. - DOI - PubMed
    1. Postuma R.B., Berg D., Stern M., Poewe W., Olanow C.W., Oertel W., Obeso J., Marek K., Litvan I., Lang A.E., et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 2015;30:1591–1601. doi: 10.1002/mds.26424. - DOI - PubMed
    1. Postuma R.B., Berg D. Prodromal Parkinson’s Disease: The Decade Past, the Decade to Come. Mov. Disord. 2019;34:665–675. doi: 10.1002/mds.27670. - DOI - PubMed